TrialThe Lancet. Oncology2013

Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.

Thomas E Hutson et al.PubMed ↗Publisher ↗

No numbers read from the abstract.